Orally Disintegrating Tablet Manufacture via Direct Powder Compression Using Cellulose Nanofiber as a Functional Additive.
cellulose nanofiber
direct powder compression
disintegration
hardness
orally disintegrating tablet
Journal
AAPS PharmSciTech
ISSN: 1530-9932
Titre abrégé: AAPS PharmSciTech
Pays: United States
ID NLM: 100960111
Informations de publication
Date de publication:
23 Dec 2021
23 Dec 2021
Historique:
received:
23
08
2021
accepted:
01
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
28
12
2021
Statut:
epublish
Résumé
In recent years, orally disintegrating (OD) tablets have been continuously improved to increase efficacy. Herein, we focused on the benefits of cellulose nanofiber (CNF), a highly functional material, in OD tablet manufacturing. We studied its effects on the physical properties of tablets during manufacture. The analyzed tablet formulations included different content CNF (0-50%; 6 preparations), lactose hydrate, acetaminophen, and magnesium stearate (Mg-St). We measured the angles of repose and evaluated the flowability of the powder. Tablets were prepared on a tabletop and rotary tableting presses, whereafter their weight, drug content, hardness, friability, and disintegration time were evaluated. Although CNF addition slightly reduced powder flowability, continuous tableting was feasible via direct powder compression. Tablet hardness (~40 N) was comparable between CNF-containing (20%) tablets and those prepared with crystalline cellulose under 10 kN compression force. Disintegration time (~30 s) was similar between CNF-supplemented tablets and those supplemented with low-substituted hydroxypropyl cellulose, crospovidone, or croscarmellose sodium. At higher CNF fractions, tablet hardness increased, while friability decreased. Adding ≥30% CNF prolonged the tablet disintegration time. To set the optimized manufacturing condition for ensuring the desired tablet physical properties, we created contour plots for evaluating the effects of CNF concentration and compression force on hardness and disintegration time. A CNF concentration of 10-20% and a compression force of 12-13 kN would allow for the preparation of tablets with a hardness ≥30 N and a disintegration time ≤60 s. Altogether, addition of CNF to the OD tablet formulation for direct powder compression enhanced hardness and disintegration.
Identifiants
pubmed: 34950985
doi: 10.1208/s12249-021-02194-5
pii: 10.1208/s12249-021-02194-5
doi:
Substances chimiques
Powders
0
Tablets
0
Cellulose
9004-34-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37Informations de copyright
© 2021. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Références
Kawashima Y. The Society of Powder Technology, Japan: division of particulate preparation and design, editors. Compression molding technology of powder. Tokyo: Nikkan Kogyo Shimbun, Ltd.; 1998. p. 3–11.
Blanco M, Alcalá M. Content uniformity and tablet hardness testing of intact pharmaceutical tablets by near infrared spectroscopy. Anal Chim Acta. 2006;557:353–9. https://doi.org/10.1016/j.aca.2005.09.070 .
doi: 10.1016/j.aca.2005.09.070
Moes JJ, Ruijken MM, Gout E, Frijlink HW, Ugwoke MI. Application of process analytical technology in tablet process development using NIR spectroscopy: blend uniformity, content uniformity and coating thickness measurements. Int J Pharm. 2008;357:108–18. https://doi.org/10.1016/j.ijpharm.2008.01.062 .
doi: 10.1016/j.ijpharm.2008.01.062
pubmed: 18394831
Goodwin DJ, van den Ban S, Denham M, Barylski I. Real time release testing of tablet content and content uniformity. Int J Pharm. 2018;537:183–92. https://doi.org/10.1016/j.ijpharm.2017.12.011 .
doi: 10.1016/j.ijpharm.2017.12.011
pubmed: 29229511
Wang X, Cui F, Yonezawa Y, Sunada H. Preparation and evaluation of combination tablet containing incompatible active ingredients. Chem Pharm Bull (Tokyo). 2003;51:772–8. https://doi.org/10.1248/cpb.51.772 .
doi: 10.1248/cpb.51.772
pubmed: 12843581
Takeuchi Y, Yoshida M, Ito A, Sunada H. Uniformity of drug content during pharmaceutical dry granulating by roller compaction and tableting processes. J Drug Deliv Sci Technol. 2009;19:119–24. https://doi.org/10.1016/S1773-2247(09)50019-6 .
doi: 10.1016/S1773-2247(09)50019-6
Mahours GM, Shaaban DEZ, Shazly GA, Auda SH. The effect of binder concentration and dry mixing time on granules, tablet characteristics and content uniformity of low dose drug in high shear wet granulation. J Drug Deliv Sci Technol. 2017;39:192–9. https://doi.org/10.1016/j.jddst.2017.03.014 .
doi: 10.1016/j.jddst.2017.03.014
Sun WJ, Aburub A, Sun CC. Particle engineering for enabling a formulation platform suitable for manufacturing low-dose tablets by direct compression. J Pharm Sci. 2017;106:1772–7. https://doi.org/10.1016/j.xphs.2017.03.005 .
doi: 10.1016/j.xphs.2017.03.005
pubmed: 28322940
Furukawa K. Development of excipients for direct compression by fluidized bed granulation. Pharm Tech Jpn. 2018;34:93–7.
Yoshida I, Sakai Y. The applications of the content uniformity test and the weight variation test on process validation tests of multiple ingredient preparations. Chem Pharm Bull. 1999;47:678–83. https://doi.org/10.1248/cpb.47.678 .
doi: 10.1248/cpb.47.678
Katori N, Aoyagi N, Kojima S. The study of the applicability of content uniformity and weight variation test—the state of commercial tablets and capsules in Japan. Chem Pharm Bull. 2001;49:1412–9. https://doi.org/10.1248/cpb.49.1412 .
doi: 10.1248/cpb.49.1412
Lukášová I, Muselík J, Franc A, Goněc R, Mika F, Vetchý D. Factor analysis in optimization of formulation of high content uniformity tablets containing low dose active substance. Eur J Pharm Sci. 2017;109:541–7. https://doi.org/10.1016/j.ejps.2017.09.017 .
doi: 10.1016/j.ejps.2017.09.017
pubmed: 28912027
Makino T. The first of direct compression to accelerate pharmaceutical development and reduce cost of dosage form. Pharm Tech Jpn. 2017;33:2309–11.
Hara Y. Development of direct tableting technology for Pletaal OD tablet. Pharm Tech Jpn. 2017;33:2313–6.
Katayama T, Terasawa K, Takeuchi T, Okuda Y. Formulation design of olanzapine orally disintegration tablet “TOWA”—direct compression—The first choice in the manufacture of tablets. Pharm Tech Jpn. 2017;33:2317–20.
Makino T, Hoshino T, Tsuchiya A, Oneda Y. Analysis and evaluation the super-high speed compression—securing of content uniformity. Pharm Tech Jpn. 2018;34:283–7.
United States Food and Drug Administration. Orally disintegrating tablets. Guidance for industry. Rockville. Maryland: FDA; 2008.
Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst. 2004;21:433–76. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v21.i6.10 .
doi: 10.1615/CritRevTherDrugCarrierSyst.v21.i6.10
pubmed: 15658933
Goel H, Rai P, Rana V, Tiwary AK. Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv Formul. 2008;2:258–74. https://doi.org/10.2174/187221108786241660 .
doi: 10.2174/187221108786241660
pubmed: 19075912
Al-Husban FA, El-Shaer AM, Jones RJ, Mohammed AR. Recent patents and trends in orally disintegrating tablets. Recent Pat Drug Deliv Formul. 2010;4:178–97. https://doi.org/10.2174/187221110793237574 .
doi: 10.2174/187221110793237574
Badgujar BP, Mundada AS. The technologies used for developing orally disintegrating tablets: a review. Acta Pharm. 2011;61:117–39. https://doi.org/10.2478/v10007-011-0020-8 .
doi: 10.2478/v10007-011-0020-8
pubmed: 21684842
Namiki N. Clinical functionality required for orally disintegrating tablets selected as the next generation type. YAKUGAKU ZASSHI. 2015;135:237–43. https://doi.org/10.1248/yakushi.14-00228-3 .
doi: 10.1248/yakushi.14-00228-3
pubmed: 25747219
Okuda Y, Irisawa Y, Okimoto K, Osawa T, Yamashita S. A new formulation for orally disintegrating tablets using a suspension spray-coating method. Int J Pharm. 2009;382:80–7. https://doi.org/10.1016/j.ijpharm.2009.08.010 .
doi: 10.1016/j.ijpharm.2009.08.010
pubmed: 19686825
Douroumis DD, Gryczke A, Schminke S. Development and evaluation of cetirizine HCl taste-masked oral disintegrating tablets. AAPS PharmSciTech. 2011;12:141–51. https://doi.org/10.1208/s12249-010-9569-7 .
doi: 10.1208/s12249-010-9569-7
pubmed: 21181510
Stirnimann T, Di Maiuta ND, Gerard DE, Alles R, Huwyler J, Puchkov M. Functionalized calcium carbonate as a novel pharmaceutical excipient for the preparation of orally dispersible tablets. Pharm Res. 2013;30:1915–25. https://doi.org/10.1007/s11095-013-1034-3 .
doi: 10.1007/s11095-013-1034-3
pubmed: 23604923
European Pharmacopoeia (2016) Orodispersible tablets. European directorate for the quality of medicines (EDQM), council of Europe, 8th ed. Strasbourg, France; 2016. p. 811.
Hu X, Li Y, Zhang E, Wang X, Xing M, Wang Q, Lei J, Huang H. Preparation and evaluation of orally disintegrating tablets containing taste-masked microcapsules of berberine hydrochloride. AAPS PharmSciTech. 2013;14:29–37. https://doi.org/10.1208/s12249-012-9880-6 .
doi: 10.1208/s12249-012-9880-6
pubmed: 23180226
Kande KV, Kotak DJ, Degani MS, Kirsanov D, Legin A, Devarajan PV. Microwave-assisted development of orally disintegrating tablets by direct compression. AAPS PharmSciTech. 2017;18:2055–66. https://doi.org/10.1208/s12249-016-0683-z .
doi: 10.1208/s12249-016-0683-z
pubmed: 27995465
Ministry of the Environment. Guidelines for the utilization and application of cellulose nanofiber towards the decarbonization and achievement of a circular economy. 2021. http://www.env.go.jp/earth/earth/ondanka/cnf/guideline_summaryen.pdf . Accessed 28 Nov 2021.
The International Organization for Standardization. TS 20477: nanotechnologies–standard terms and their definition for cellulose nanomaterial. ISO. 2017. https://www.iso.org/obp/ui/#iso:std:68153:en . Accessed 28 Nov 2021.
Plackett DV, Letchford K, Jackson JK, Burt HM. A review of nanocellulose as a novel vehicle for drug delivery. Nord Pulp Pap Res J. 2014;29:105–18. https://doi.org/10.3183/npprj-2014-29-01-p105-118 .
doi: 10.3183/npprj-2014-29-01-p105-118
Lin N, Dufresne A. Nanocellulose in biomedicine: current status and future prospect. Eur Polym J. 2014;59:302–25. https://doi.org/10.1016/j.eurpolymj.2014.07.025 .
doi: 10.1016/j.eurpolymj.2014.07.025
Svagan AJ, Benjamins JW, Al-Ansari Z, Shalom DB, Müllertz A, Wågberg L, et al. Solid cellulose nanofiber based foams –towards facile design of sustained drug delivery systems. J Control Release. 2016;244:74–82. https://doi.org/10.1016/j.jconrel.2016.11.009 .
doi: 10.1016/j.jconrel.2016.11.009
pubmed: 27847327
Bannow J, Benjamins JW, Wohlert J, Löbmann K, Svagan AJ. Solid nanofoams based on cellulose nanofibers and indomethacin—the effect of processing parameters and drug content on material structure. Int J Pharm. 2017;526:291–9. https://doi.org/10.1016/j.ijpharm.2017.04.041 .
doi: 10.1016/j.ijpharm.2017.04.041
pubmed: 28434935
Löbmann K, Svagan AJ. Cellulose nanofibers as excipient for the delivery of poorly soluble drugs. Int J Pharm. 2017;533:285–97. https://doi.org/10.1016/j.ijpharm.2017.09.064 .
doi: 10.1016/j.ijpharm.2017.09.064
pubmed: 28951349
Kargarzadeh H, Mariano M, Huang J, Lin N, Ahmad I, Dufresne A, Thomas S. Recent developments on nanocellulose reinforced polymer nanocomposites: a review. Polymer. 2017;132:368–93. https://doi.org/10.1016/j.polymer.2017.09.043 .
doi: 10.1016/j.polymer.2017.09.043
Sharip NS, Ariffin H. Cellulose nanofibrils for biomaterial applications. Mater Today Proc. 2019;16:1959–68. https://doi.org/10.1016/j.matpr.2019.06.074 .
doi: 10.1016/j.matpr.2019.06.074
Meneguin AB, da Silva BH, Sábio RM, de Sousa PZ, Manieri KF, de Freitas LAP, et al. Spray-dried bacterial cellulose nanofibers: a new generation of pharmaceutical excipient intended for intestinal drug delivery. Carbohydr Polym. 2020;249:116838. https://doi.org/10.1016/j.carbpol.2020.116838 .
doi: 10.1016/j.carbpol.2020.116838
pubmed: 32933682
Liu S, Qamar SA, Qamar M, Basharat K, Bilal M. Engineered nanocellulose-based hydrogels for smart drug delivery applications. Int J Biol Macromol. 2021;181:275–90. https://doi.org/10.1016/j.ijbiomac.2021.03.147 .
doi: 10.1016/j.ijbiomac.2021.03.147
pubmed: 33781811
Raghav N, Sharma MR, Kennedy JF. Nanocellulose: a mini-review on types and use in drug delivery systems. Carbohydr Polym Technol Appl. 2021;2:100031. https://doi.org/10.1016/j.carpta.2020.100031 .
doi: 10.1016/j.carpta.2020.100031
The Japanese Pharmacopoeia. General information, tablet hardness test. The Japanese Pharmacopoeia. Ministry of Health, Labour and Welfare, 18th ed; 2021. p 2641‒2 http://www.mhlw.go.jp/content/11120000/000788362.pdf .
The Japanese Pharmacopoeia. General information, tablet friability test. The Japanese Pharmacopoeia. Ministry of Health, Labour and Welfare, 18th ed; 2021. p. 2642. https://www.mhlw.go.jp/content/11120000/000788362.pdf .
The Japanese Pharmacopoeia. General tests, processes and apparatus, uniformity of dosage units. The Japanese Pharmacopoeia. Ministry of Health, Labour and Welfare, 18th ed; 2021. p. 147‒9. https://www.mhlw.go.jp/content/11120000/000788359.pdf .
Guilford JP. Fundamental statistics in psychology and education. New York: McGraw-Hill; 1956.
Carr RL. Evaluating flowability properties of solids. Chem Eng. 1965;18:163–8.